• Embed Doc
  • Copy Link
  • Readcast
  • Collections
  • CommentGo Back
Download
 
 
FORWARD INQUIRIES TO:
SAFC PharmaDavid FeldkerVice President, SAFC+1-314-289-8467 
MEDIA INQUIRIES: IMPRESS PUBLIC RELATIONS
Richard Kerns+ 44-(0)161-728-5880richard@impress-pr.com Mark Button+1-503-616-3817mark@impress-pr.com 
SAFC PHARMA INSTALLS THE INDUSTRY’S FIRST COMMERCIALDUAL WAVELENGTH X-RAY DIFFRACTOMETER
 Allows Increased Throughput for Challenging Single Crystal Analyses
ST. LOUIS, MO. and CPhI, MADRID, Spain, October 13, 2009 –
SAFC Pharma
 ® 
, a businesssegment of SAFC
 ® 
, a member of the Sigma-Aldrich
 ® 
Group (NASDAQ: SIAL), todayannounced that its Pharmorphix
 ® 
Solid State Research Laboratories in Cambridge, UK, haveinstalled a new single crystal X-ray diffraction system. The
Oxford Diffraction SuperNova 
TM 
 system, which can determine the crystal structures from the most challenging crystal samples,is the first industrial installation of this state-of-the-art instrumentation anywhere in the world.Equipped with a powerful high flux dual wavelength microsource X-ray generator, theSuperNova instrument is capable of performing single crystal X-ray analyses on smallmicrocrystalline fragments with dimensions of down to 30 to 50 microns. The dual wavelengthcapability will allow the rigorous determination of absolute stereochemistry of chemical entitieswhich contain first row elements only.Solid-form characterization and research is an essential part of the drug development process.A fundamental understanding of the physical properties of active pharmaceutical ingredients(APIs) allows for the selection of the optimal solid-form to ensure patient benefit such asefficacy and safety, and protect intellectual property.
 (more)
 
of 00

Leave a Comment

You must be to leave a comment.
Submit
Characters: ...
You must be to leave a comment.
Submit
Characters: ...